Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab.

Schützinger C, Gaiger A, Thalhammer R, Vesely M, Fritsche-Polanz R, Schwarzinger I, Ohler L, Simonitsch-Klupp I, Reinhard F, Jäger U.

Leukemia. 2005 Nov;19(11):2005-8. No abstract available.

PMID:
16193089
2.

Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.

Au WY, Lam CC, Chim CS, Pang AW, Kwong YL.

Leuk Res. 2005 Oct;29(10):1213-5. Epub 2005 Apr 25.

PMID:
16111536
4.

[Pathophysiology and treatment of large granular lymphocyte leukemia-associated pure red cell aplasia].

Fujishima N.

Rinsho Ketsueki. 2010 Aug;51(8):589-96. Review. Japanese. No abstract available.

PMID:
20805663
5.

Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.

Thachil J, Salim R.

Leuk Res. 2007 Jul;31(7):1025-6. Epub 2006 Sep 26. No abstract available.

PMID:
17005249
6.

Alemtuzumab for B-cell chronic lymphocytic leukemia.

Robak T.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1033-51. doi: 10.1586/14737140.8.7.1033. Review.

PMID:
18588450
7.

Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.

Monjanel H, Hourioux C, Arbion F, Colombat P, Lissandre S, Regner MP, Senecal D.

Leuk Res. 2010 Aug;34(8):e197-9. doi: 10.1016/j.leukres.2010.01.019. Epub 2010 Mar 7. No abstract available.

PMID:
20211489
8.

Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia.

Rosenblum MD, LaBelle JL, Chang CC, Margolis DA, Schauer DW, Vesole DH.

Blood. 2004 Mar 1;103(5):1969-71. No abstract available.

9.

Refractory idiopathic pure red cell aplasia complicated by immune thrombocytopenia successfully treated with subcutaneous alemtuzumab.

Pham DC, Guthrie TH, Villas BH, Salazar E.

Am J Hematol. 2008 Jul;83(7):603. doi: 10.1002/ajh.21155. No abstract available.

10.

The role of alemtuzumab in the management of T-cell malignancies.

Dearden C.

Semin Oncol. 2006 Apr;33(2 Suppl 5):S44-52. Review.

PMID:
16720203
11.

Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia.

Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P.

Br J Haematol. 2010 Aug;150(4):480-1. doi: 10.1111/j.1365-2141.2010.08218.x. Epub 2010 Apr 28. No abstract available.

PMID:
20456357
12.

T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.

Aribi A, Huh Y, Keating M, O'brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F.

Leuk Res. 2007 Jul;31(7):939-45. Epub 2006 Oct 12.

PMID:
17045649
13.

Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.

Laurenti L, Piccioni P, Tarnani M, Efremov DG, Fiorini A, Garzia M, Sica S.

Haematologica. 2005 Aug;90(8):1143-5.

14.
15.

[T-cell large granular lymphocytic leukemia associated with pure red cell aplasia, successfully treated with cyclophosphamide].

Mátrai Z, Lelkes G, Milosevits J, Páldiné HP, Pecze K.

Orv Hetil. 1997 Aug 17;138(33):2075-80. Review. Hungarian.

PMID:
9304100
16.

Receptor-directed therapy of T-cell leukemias and lymphomas.

Morris JC, Waldmann TA, Janik JE.

J Immunotoxicol. 2008 Apr;5(2):235-48. doi: 10.1080/15476910802129661. Review.

PMID:
18569395
17.

Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab.

Crowley B, Woodcock B.

Br J Haematol. 2002 Oct;119(1):279-80. No abstract available.

PMID:
12358942
18.

Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.

Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE.

Br J Haematol. 2010 Jun;149(6):907-10. doi: 10.1111/j.1365-2141.2010.08134.x. Epub 2010 Mar 1. No abstract available.

PMID:
20201944
19.

Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.

Chaar BT, Petruska PJ.

Am J Hematol. 2007 May;82(5):417. No abstract available.

20.

Supplemental Content

Support Center